Lag-3 Targeted Development Summit' - Jan 2022
Marc is opening the show and Federik is sharing his Lag-3 journey since 1988...
Also, interesting that Cardiff Uni is presenting small molecule (non-PD1 combinations)...see point 3 below....
June 2021:-
"Immutep (IMM) is commencing a new research program as part of its clinical development pipeline of immunotherapies for cancer and autoimmune disease.
The biotechnology company will continue to work with Cardiff University under a collaboration project which began in 2019 with the objective of developing a small molecule anti-LAG treatment for cancer patients.This research program will draw on the expertise of the University Theme Lead in Immunology in the College of Biomedical Life Sciences Professors Andrew Godkin, as well as Professor of Medicinal Chemistry at the School of Pharmacy and Pharmaceutical Sciences Andrea Brancale.
“We are excited to progress this project with the world leading scientists at Cardiff University and continue our work to develop novel LAG-3 therapeutics, especially as there are already some exciting early results from our joint effort,” Immutep CEO Marc Voigt said.
News: IMM Immutep Receives Positive EMA Scientific Advice For Further Clinical Development Of EFTI..., page-26
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |